The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
T. Hansen
Other Remuneration - Roche
R. d. Christensen
Consultant or Advisory Role - Roche
Honoraria - Roche
R. F. Andersen
No relevant relationships to disclose
K. G. Spindler
Other Remuneration - Roche
A. Johnsson
No relevant relationships to disclose
A. K. M. Jakobsen
No relevant relationships to disclose